View Item 

Show simple item record

APOE effect on Alzheimer’s disease biomarkers in older adults with significant memory concern
dc.contributor.authorRisacher, Shannon L.
dc.contributor.authorKim, Sungeun
dc.contributor.authorNho, Kwangsik
dc.contributor.authorForoud, Tatiana
dc.contributor.authorShen, Li
dc.contributor.authorPetersen, Ronald C.
dc.contributor.authorJack, Clifford R.
dc.contributor.authorBeckett, Laurel A.
dc.contributor.authorAisen, Paul S.
dc.contributor.authorKoeppe, Robert A.
dc.contributor.authorJagust, William J.
dc.contributor.authorShaw, Leslie M.
dc.contributor.authorTrojanowski, John Q.
dc.contributor.authorWeiner, Michael W.
dc.contributor.authorSaykin, Andrew J.
dc.date.accessioned2020-01-13T15:05:19Z
dc.date.available2020-01-13T15:05:19Z
dc.date.issued2015-12
dc.identifier.citationRisacher, Shannon L.; Kim, Sungeun; Nho, Kwangsik; Foroud, Tatiana; Shen, Li; Petersen, Ronald C.; Jack, Clifford R.; Beckett, Laurel A.; Aisen, Paul S.; Koeppe, Robert A.; Jagust, William J.; Shaw, Leslie M.; Trojanowski, John Q.; Weiner, Michael W.; Saykin, Andrew J. (2015). "APOE effect on Alzheimer’s disease biomarkers in older adults with significant memory concern." Alzheimer’s & Dementia 11(12): 1417-1429.
dc.identifier.issn1552-5260
dc.identifier.issn1552-5279
dc.identifier.urihttps://hdl.handle.net/2027.42/152583
dc.description.abstractIntroductionThis study assessed apolipoprotein E (APOE) ε4 carrier status effects on Alzheimer’s disease imaging and cerebrospinal fluid (CSF) biomarkers in cognitively normal older adults with significant memory concerns (SMC).MethodsCognitively normal, SMC, and early mild cognitive impairment participants from Alzheimer’s Disease Neuroimaging Initiative were divided by APOE ε4 carrier status. Diagnostic and APOE effects were evaluated with emphasis on SMC. Additional analyses in SMC evaluated the effect of the interaction between APOE and [18F]Florbetapir amyloid positivity on CSF biomarkers.ResultsSMC ε4+ showed greater amyloid deposition than SMC ε4−, but no hypometabolism or medial temporal lobe (MTL) atrophy. SMC ε4+ showed lower amyloid beta 1–42 and higher tau/p‐tau than ε4−, which was most abnormal in APOE ε4+ and cerebral amyloid positive SMC.DiscussionSMC APOE ε4+ show abnormal changes in amyloid and tau biomarkers, but no hypometabolism or MTL neurodegeneration, reflecting the at‐risk nature of the SMC group and the importance of APOE in mediating this risk.
dc.publisherElsevier B.V.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherPET
dc.subject.otherStructural magnetic resonance imaging (MRI)
dc.subject.otherCerebrospinal fluid
dc.subject.otherCSF
dc.subject.otherAlzheimer’s Disease Neuroimaging Initiative
dc.subject.otherADNI
dc.subject.otherAPOE
dc.subject.otherSignificant memory concern
dc.subject.otherSMC
dc.subject.otherSubjective cognitive decline
dc.subject.otherSCD
dc.subject.otherApolipoprotein E
dc.subject.otherNeuroimaging
dc.subject.other[18F]Florbetapir PET
dc.subject.other[18F]Fluorodeoxyglucose
dc.subject.otherFDG
dc.titleAPOE effect on Alzheimer’s disease biomarkers in older adults with significant memory concern
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelNeurology and Neurosciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/152583/1/alzjjalz201503003.pdf
dc.identifier.doi10.1016/j.jalz.2015.03.003
dc.identifier.sourceAlzheimer’s & Dementia
dc.identifier.citedreferenceBateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012; 367: 795 – 804
dc.identifier.citedreferenceGifford KA, Liu D, Lu Z, Tripodis Y, Cantwell NG, Palmisano J, et al. The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults. Alzheimers Dement. 2013; 10: 319 – 327
dc.identifier.citedreferenceGlodzik‐Sobanska L, Reisberg B, De Santi S, Babb JS, Pirraglia E, Rich KE, et al. Subjective memory complaints: presence, severity and future outcome in normal older subjects. Dement Geriatr Cogn Disord. 2007; 24: 177 – 184
dc.identifier.citedreferenceHohman TJ, Beason‐Held LL, Lamar M, Resnick SM. Subjective cognitive complaints and longitudinal changes in memory and brain function. Neuropsychology. 2011; 25: 125 – 130
dc.identifier.citedreferenceJessen F, Wiese B, Bachmann C, Eifflaender‐Gorfer S, Haller F, Kolsch H, et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010; 67: 414 – 422
dc.identifier.citedreferenceJessen F, Wolfsgruber S, Wiese B, Bickel H, Mosch E, Kaduszkiewicz H, et al. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement. 2014; 10: 76 – 83
dc.identifier.citedreferenceJonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population‐based studies. Int J Geriatr Psychiatry. 2000; 15: 983 – 991
dc.identifier.citedreferenceNunes T, Fragata I, Ribeiro F, Palma T, Maroco J, Cannas J, et al. The outcome of elderly patients with cognitive complaints but normal neuropsychological tests. J Alzheimers Dis. 2010; 19: 137 – 145
dc.identifier.citedreferenceRamakers IH, Visser PJ, Aalten P, Boesten JH, Metsemakers JF, Jolles J, et al. Symptoms of preclinical dementia in general practice up to five years before dementia diagnosis. Dement Geriatr Cogn Disord. 2007; 24: 300 – 306
dc.identifier.citedreferenceReid LM, Maclullich AM. Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord. 2006; 22: 471 – 485
dc.identifier.citedreferenceReisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010; 6: 11 – 24
dc.identifier.citedreferenceChao LL, Mueller SG, Buckley ST, Peek K, Raptentsetseng S, Elman J, et al. Evidence of neurodegeneration in brains of older adults who do not yet fulfill MCI criteria. Neurobiol Aging. 2010; 31: 368 – 377
dc.identifier.citedreferenceErk S, Spottke A, Meisen A, Wagner M, Walter H, Jessen F. Evidence of neuronal compensation during episodic memory in subjective memory impairment. Arch Gen Psychiatry. 2011; 68: 845 – 852
dc.identifier.citedreferenceJessen F, Feyen L, Freymann K, Tepest R, Maier W, Heun R, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006; 27: 1751 – 1756
dc.identifier.citedreferenceRodda J, Dannhauser T, Cutinha DJ, Shergill SS, Walker Z. Subjective cognitive impairment: functional MRI during a divided attention task. Eur Psychiatry. 2011; 26: 457 – 462
dc.identifier.citedreferenceScheef L, Spottke A, Daerr M, Joe A, Striepens N, Kolsch H, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology. 2012; 79: 1332 – 1339
dc.identifier.citedreferenceStewart R, Godin O, Crivello F, Maillard P, Mazoyer B, Tzourio C, et al. Longitudinal neuroimaging correlates of subjective memory impairment: 4‐year prospective community study. Br J Psychiatry. 2011; 198: 199 – 205
dc.identifier.citedreferenceStriepens N, Scheef L, Wind A, Meiberth D, Popp J, Spottke A, et al. Interaction effects of subjective memory impairment and ApoE4 genotype on episodic memory and hippocampal volume. Psychol Med. 2011; 41: 1997 – 2006
dc.identifier.citedreferenceEspeseth T, Westlye LT, Fjell AM, Walhovd KB, Rootwelt H, Reinvang I. Accelerated age‐related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. Neurobiol Aging. 2008; 29: 329 – 340
dc.identifier.citedreferenceVisser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund‐Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009; 8: 619 – 627
dc.identifier.citedreferenceWang Y, Risacher SL, West JD, McDonald BC, Magee TR, Farlow MR, et al. Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. J Alzheimers Dis. 2013; 35: 751 – 760
dc.identifier.citedreferenceWang Y, West JD, Flashman LA, Wishart HA, Santulli RB, Rabin LA, et al. Selective changes in white matter integrity in MCI and older adults with cognitive complaints. Biochim Biophys Acta. 2012; 1822: 423 – 430
dc.identifier.citedreferenceBarnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology. 2006; 67: 1581 – 1585
dc.identifier.citedreferenceMosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik‐Sobanska L, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry. 2008; 63: 609 – 618
dc.identifier.citedreferenceRowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010; 31: 1275 – 1283
dc.identifier.citedreferenceJack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12: 207 – 216
dc.identifier.citedreferenceRisacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, et al. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E‐MCI). Front Aging Neurosci. 2013; 5: 11
dc.identifier.citedreferenceJagust WJ, Landau SM Alzheimer’s Disease Neuroimaging I. Apolipoprotein E, not fibrillar beta‐amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci. 2012; 32: 18227 – 18233
dc.identifier.citedreferenceJack CR Jr., Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, et al. Update on the magnetic resonance imaging core of the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 2010; 6: 212 – 220
dc.identifier.citedreferenceJagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010; 6: 221 – 229
dc.identifier.citedreferenceTrojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010; 6: 230 – 238
dc.identifier.citedreferencePetersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010; 74: 201 – 209
dc.identifier.citedreferenceSaykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, et al. Alzheimer’s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement. 2010; 6: 265 – 273
dc.identifier.citedreferenceWeiner MW, Aisen PS, Jack CR Jr., Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer’s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 2010; 6: 202 – 211 e7
dc.identifier.citedreferenceBrett M, Anton JL, Valabregue R, Poline J‐B. Region of interest analysis using an SPM toolbox [abstract]. Presented at the 8th international conference on functional mapping of the human brain, June 2–6, 2002. Sendai, Japan 2002.
dc.identifier.citedreferenceJack CR Jr., Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008; 27: 685 – 691
dc.identifier.citedreferenceDale A, Fischl B, Sereno M. Cortical surface‐based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999; 9: 179 – 194
dc.identifier.citedreferenceFischl B, Sereno M, Dale A. Cortical surface‐based analysis. II: inflation, flattening, and a surface‐based coordinate system. Neuroimage. 1999; 9: 195 – 207
dc.identifier.citedreferenceShaw LM, Vanderstichele H, Knapik‐Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011; 121: 597 – 609
dc.identifier.citedreferenceShaw LM, Vanderstichele H, Knapik‐Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease Neuroimaging Initiative subjects. Ann Neurol. 2009; 65: 403 – 413
dc.identifier.citedreferenceLandau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid‐beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013; 54: 70 – 77
dc.identifier.citedreferenceSmith CD, Andersen AH, Gold BT. Structural brain alterations before mild cognitive impairment in ADNI: validation of volume loss in a predefined antero‐temporal region. J Alzheimers Dis. 2012; 31 (Suppl 3): S49 – S58
dc.identifier.citedreferenceStriepens N, Scheef L, Wind A, Popp J, Spottke A, Cooper‐Mahkorn D, et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord. 2010; 29: 75 – 81
dc.identifier.citedreferenceFortea J, Sala‐Llonch R, Bartres‐Faz D, Llado A, Sole‐Padulles C, Bosch B, et al. Cognitively preserved subjects with transitional cerebrospinal fluid ss‐amyloid 1‐42 values have thicker cortex in Alzheimer’s disease vulnerable areas. Biol Psychiatry. 2011; 70: 183 – 190
dc.identifier.citedreferenceFortea J, Sala‐Llonch R, Bartres‐Faz D, Bosch B, Llado A, Bargallo N, et al. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis. 2010; 22: 909 – 922
dc.identifier.citedreferenceChien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF‐tau radioligand [F18]‐T808. J Alzheimers Dis. 2014; 38: 171 – 184
dc.identifier.citedreferenceMaruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013; 79: 1094 – 1108
dc.identifier.citedreferenceWishart HA, Saykin AJ, McAllister TW, Rabin LA, McDonald BC, Flashman LA, et al. Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology. 2006; 67: 1221 – 1224
dc.identifier.citedreferenceAlzheimer’s Association. 2014 Alzheimer’s disease facts and figures. Alzheimers Dement. 2014; 10: e47 – e92
dc.identifier.citedreferenceSperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7: 280 – 292
dc.identifier.citedreferenceJessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014; 10: 844 – 852
dc.identifier.citedreferenceSaykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006; 67: 834 – 842
dc.identifier.citedreferenceCaselli RJ, Chen K, Locke DE, Lee W, Roontiva A, Bandy D, et al. Subjective cognitive decline: self and informant comparisons. Alzheimers Dement. 2014; 10: 93 – 98
dc.identifier.citedreferenceGallassi R, Oppi F, Poda R, Scortichini S, Stanzani Maserati M, Marano G, et al. Are subjective cognitive complaints a risk factor for dementia?. Neurol Sci. 2010; 31: 327 – 336
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
alzjjalz201503003.pdf
Size:
2.771MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.